These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17724438)

  • 21. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
    Gupta V; Ball SE; Sage D; Ortin M; Freires M; Gordon-Smith EC; Marsh JC
    Bone Marrow Transplant; 2005 Mar; 35(5):467-71. PubMed ID: 15665848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
    Dorsey MJ; Petrovic A; Morrow MR; Dishaw LJ; Sleasman JW
    Immunol Res; 2009; 44(1-3):179-84. PubMed ID: 19471859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unusual complications after bone marrow transplantation for dyskeratosis congenita.
    Rocha V; Devergie A; Socié G; Ribaud P; Espérou H; Parquet N; Gluckman E
    Br J Haematol; 1998 Oct; 103(1):243-8. PubMed ID: 9792316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
    Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
    Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
    Osborne WL; Lennard AL
    Haematologica; 2005 Jan; 90(1):ECR05. PubMed ID: 15653459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
    Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
    Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
    Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Byrd JC; Rai KR
    Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
    [No Abstract]   [Full Text] [Related]  

  • 31. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
    Popat U; Carrum G; May R; Lamba R; Krance RA; Heslop HE; Brenner MK
    Bone Marrow Transplant; 2005 Jun; 35(12):1127-32. PubMed ID: 15834432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
    Styczynski J; Tallamy B; Waxman I; van de Ven C; Milone MC; Shaw LM; Harrison L; Morris E; Satwani P; Bhatia M; George D; Bradley MB; Garvin JH; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2011 Jun; 46(6):790-9. PubMed ID: 20818441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen.
    Brazzola P; Duval M; Fournet JC; Gauvin F; Dalle JH; Champagne J; Champagne MA
    Bone Marrow Transplant; 2005 Dec; 36(12):1103-5; author reply 1105. PubMed ID: 16205731
    [No Abstract]   [Full Text] [Related]  

  • 34. [Bone marrow failure due to telomere associated gene mutation].
    Yamaguchi H; Dan K
    Rinsho Ketsueki; 2010 Aug; 51(8):646-53. PubMed ID: 20805671
    [No Abstract]   [Full Text] [Related]  

  • 35. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.
    Kang HJ; Shin HY; Choi HS; Ahn HS
    Bone Marrow Transplant; 2004 Dec; 34(11):939-43. PubMed ID: 15489866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation.
    Ghavamzadeh A; Alimoghadam K; Nasseri P; Jahani M; Khodabandeh A; Ghahremani G
    Bone Marrow Transplant; 1999 Feb; 23(3):299-301. PubMed ID: 10084264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffuse hemorrhagic colitis in a patient with dyskeratosis congenita after nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Ehlert K; Rossig C; Groll AH; Beyna T; Froehlich B; Juergens H
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e41-4. PubMed ID: 25000468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome.
    Longhurst HJ; Taussig D; Haque T; Syndercombe-Court D; Cavenagh J; Edgar JD; Helbert MR
    Br J Haematol; 2002 Feb; 116(2):497-9. PubMed ID: 11841458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
    Pollyea DA; Artz AS; Stock W; Daugherty C; Godley L; Odenike OM; Rich E; Smith SM; Zimmerman T; Zhang Y; Huo D; Larson R; van Besien K
    Bone Marrow Transplant; 2007 Dec; 40(11):1027-32. PubMed ID: 17846595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
    Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
    Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.